Here is how PrEP works:

• When CD4 cells are infected with HIV, they become little factories that make thousands of new viruses each day
• HIV drugs work by blocking HIV from making copies of itself
• If an HIV-negative woman already has HIV drugs in her bloodstream when she is exposed to HIV, for example during sex without a condom, the medicine can keep the virus from making enough copies of itself to "take hold" and prevent her from getting HIV

11 branches of PULSE CLINIC are now open 7 days a week in all 4 countries; Thailand, Hong Kong, Malaysia and Singapore.
But if you can't visit us at the clinic for whatever reasons, You can buy PrEP online from our licensed clinics.

• Make sure we have your prescription and or lab results before ordering PrEP
• Make sure you send us a copy of passport and lab results from your doctor or your labs or send us prescription from your doctor. We’ll re-check your results, then we can provide you 3 to 6 month’s supply each time.

PrEP offers women almost 100% protection against HIV when taken correctly.

Approval for Daily Oral PrEP

In July 2012, the US Food and Drug Administration (FDA) approved the daily use of Truvada (tenofovir disoproxil fumarate plus emtricitabine, or TDF/FTC) as PrEP for sexually active adults at risk of getting HIV. Truvada is often used as part of combination drug treatment for HIV. This was the first time the FDA approved any medication for the prevention of HIV. The World Health Organization (WHO) released updated guidelines in June 2016 that expand earlier recommendations. It now recommends that daily oral PrEP be offered as an additional prevention method to all people at substantial risk of getting HIV. The WHO has approved the use of either Viread (tenofovir disoproxil fumarate) or Truvada for this purpose. However, each country must individually approve the use of Truvada or Viread as PrEP and determine how it will provide the drug.

Several clinical trials have shown that taking Truvada as oral PrEP (one pill by mouth daily) lowers the risk of acquiring HIV from sex by more than 90%. That risk is reduced by more than 70% among people who inject drugs.

References 

1.McCormack S, Dunn D. Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study. CROI 2015; Seattle, Washington, 2015.
2.Molina J, Capitant C, Spire B, Pialoux G, Chidiac C, Charreau I, et al., editors. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Conference on Retroviruses and Opportunistic Infections;